OBJECTIVES: To test the effect of systemic chemotherapy on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB). MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results registry (2004 to 2016), we identified patients with localized (T2-3N0M0), regional (T4N0M0/TanyN1-3M0), and metastatic (TanyNanyM1) ADKUB. Temporal trends, Kaplan-Meier plots, and multivariable Cox regression models were used before and after 1:1 propensity score matching and inverse probability of treatment weighting. RESULTS: Of 1537 patients with ADKUB, 834 (54.0%), 363 (23.5%), and 340 (22.5%) harbored localized, regional, and metastatic disease, respectively. The rates of chemotherapy use increased in localized (estimated annual percentage change [EAPC]: +2.7%; P=0.03) and regional ADKUB (EAPC: +2.4%; P=0.04). Conversely, chemotherapy rates remained stable in metastatic patients (EAPC: +1.6%; P=0.4). In multivariable Cox regression models, chemotherapy use was associated with lower CSM in metastatic ADKUB (hazard ratio [HR]: 0.5; P=0.003), but not in either localized (HR: 0.8; P=0.2) or in regional ADKUB (HR: 1.0; P=0.9). In metastatic ADKUB, the benefit of chemotherapy on CSM persisted after 1:1 propensity score matching (HR: 0.6; P=0.002) and after inverse probability of treatment weighting (HR: 0.4; P<0.001). CONCLUSIONS: Chemotherapy improves survival in metastatic ADKUB. However, only one out of 2 such patients benefit from chemotherapy. In consequence, greater emphasis on chemotherapy use may be warranted in these patients. Conversely, no benefit was identified in localized or regional ADKUB.

Cancer Prognostics and Health Outcomes Unit Division of Urology University of Montreal Health Center Montreal QC Canada

Department of Medical and Surgical Specialties Radiological Science and Public Health Urology Unit ASST Spedali Civili of Brescia University of Brescia Brescia

Department of Oncology and Hemato Oncology University of Milan Milan

Department of Urology 2nd Faculty of Medicine Charles University Prag Czech Republicm

Department of Urology and Division of Experimental Oncology URI Urological Research Institute IRCCS San Raffaele Scientific Institute

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology European Institute of Oncology IRCCS

Department of Urology IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico

Department of Urology San Luigi Gonzaga Hospital University of Turin Turin Italy

Department of Urology University Hospital Frankfurt Frankfurt am Main Germany

Department of Urology University of Texas Southwestern Dallas TX

Department of Urology Weill Cornell Medical College New York NY

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

See more in PubMed

Moschini M, D’Andrea D, Korn S, et al. Characteristics andclinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14:651–668.

Baumeister P, Zamboni S, Mattei A, et al. Histological variants in non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8:34–38.

Manunta A, Vincendeau S, Kiriakou G, et al. Non-transitional cell bladder carcinomas. BJU Int. 2005;95:497–502.

Vetterlein MW, Seisen T, Leow JJ, et al. Effect of nonurothelial histologic variants on the outcomes of radical cystectomy for nonmetastatic muscle-invasive urinary bladder cancer. Clin Genitourin Cancer. 2018;16:e129–e139.

Lughezzani G, Sun M, Jeldres C, et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology. 2010;75:376–381.

Zaffuto E, Gazdovich S, Leyh-Bannurah SR, et al. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. Int J Urol. 2017;24:117–123.

Witjes JA, Lebret T, Compérat EM, et al. Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–475.

Flaig TW, Spiess PE, Agarwal N, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Cancer Netw. 2018;16:1041–1053.

Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255–259.

Hong JY, Choi MK, Uhm JE, et al. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol. 2009;26:186–192.

De Santis M, Bachner M. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol. 2007;17:363–368.

Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123:4346–4355.

Berg S, D’Andrea D, Vetterlein MW, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter? Cancer. 2019;125:1449–1458.

Logothetis CJ, Dexeus FH, Chong C, et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol. 1989;141:33–37.

Noone AM, Howlader N, Krapcho M, et al. Cancer Statistics Review, 1975-2015—SEER Statistics. Bethesda, MD: National Cancer Institute; 2018.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.

Luzzago S, Palumbo C, Rosiello G, et al. Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World J Urol. 2020. Doi: 10.1007/s00345-020-03083-5. DOI

Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer. 2006;107:721–728.

Dutta R, Abdelhalim A, Martin JW, et al. Effect of tumor location on survival in urinary bladder adenocarcinoma: a population-based analysis. Urol Oncol Semin Orig Investig. 2016;34:531.e1–531.e6.

Collazo-Lorduy A, Castillo-Martin M, Wang L, et al. Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol. 2016;70:771–775.

Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol. 2003;169:1295–1298.

Seisen T, Sun M, Leow JJ, et al. Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base. J Clin Oncol. 2019;34:29. Doi: 10.1200/JCO.2016.66.7352. DOI

Moschini M, Xylinas E, Zamboni S, et al. Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database. Eur Urol Oncol. 2020;3:94–101.

Luzzago S, Palumbo C, Rosiello G, et al. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. J Surg Oncol. 2019;120:1266–1275.

Comparison Between Urothelial and Non-Urothelial Urethral Cancer